Start of the day. #cafedeflore

RT @KrGurashi: An integrative multiparametric approach stratifies putative distinct phenotypes of blast phase chronic myelomonocytic leukem…

@KrGurashi @Kiran_Batta @somervaillelab @UoM_DCS @MCRCnews @CellRepMed Congratulations! 😍

Big congratulations to my mate @KrGurashi! What a fantastic way to kick off the year! 🎉💪

- Blast phase CMML is a molecularly and clinically distinct form of acute leukemia - RNA-seq of BP-CMML blasts identifies novel disrupted gene networks and pathways - BP-CMML subtypes exhibit distinct therapeutic vulnerabilities

AML typical mutations (CEBPA, FLT3, NPM1) identify a high-risk chronic myelomonocytic leukemia independent of CPSS molecular @MDSFoundation @aamdsif @ic_MDS @MDS_Hub @BloodAdvances #CMML #MDSsm #MPNsm

Farewell, my friend. Wishing you all the best for the next chapter! 👍💪

RT @MrinalPatnaik: Single-cell multiomics reveal divergent effects of DNMT3A- and TET2-mutant clonal hematopoiesis in inflammatory response…

RT @PriyaSriRajah: @harrisoncn1 next covered updates in myelofibrosis with a reminder of the number of scoring systems now available to ris…

RT @PriyaSriRajah: Updates for MDS with promising new agents in both low and high risk patients

RT @PriyaSriRajah: Our very own @jm_osullivan presented further updates on MPN from ASH 2024 @HT_Medical

RT @MPN_Hub: 📝 Results from a matching-adjusted indirect comparison presented by Francesca Palandri at #ASH24 show that momelotinib improve…

@HelenePasquer @BloodJournal @BenajibaLina @jjkiladjian @cic1427 Congratulations 🎉

RT @BloodJournal: Current myeloproliferative neoplasm scoring systems for clinical practice #myeloidneoplasia https…

RT @ARampotas: A very nice Sunday read on the challenges CAR-T cells face in tackling myeloid malignancies by Prof Beth Psaila (@beth_psail…

RT @mpndoc: Delighted to share our latest study led by MSTP student @TimKong_ now online @NatureComms! #mpnsm #amlsm @WashUHematology @Wash…

RT @Blood_Cancers: New criteria has reclassified a subset of pts with #MDS as having oligo-monocytic #CMML. @Ramikomrokji (@MoffittNews) &…

RT @joanhowMD: Hot off the press! CV risk factors in MPNs remain critical for modifying outcomes, and affect thrombosis risk differently wi…

RT @NicoGagelmann: 🎉Finally published🎉 Clearance of driver mutations after transplantation for myelofibrosis ⁦@NEJM⁩